AMO Pharma AMO-02 Update
Presenters include:
Joe Horrigan, Chief Medical Officer
Mike Snape, Chief Scientific Officer
Emily Fantelli, Associate Director, Clinical Development
In August 2020, AMO Pharma published the results of a Phase 2 study utilizing AMO-02 (Tideglusib) for Childhood Onset DM1 in Pediatric Neurology: [ Ссылка ]30274-5/fulltext
AMO Pharma is excited to announce they will be moving forward with the REACH-CDM Clinical Trial for AMO-02 after the US FDA and Health Canada approved their recently revised study protocols: [ Ссылка ]
Learn more about AMO Pharma at [ Ссылка ]
Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions.
Find all our upcoming Meet the DM Drug Developers dates at www.myotonic.org/meet-dm-drug-developers
For more information on myotonic dystrophy, visit www.myotonic.org
